wired bridge

Events

2019 J.P. Morgan Health Care Investor Conference

January 7–10, 2019 | San Francisco, California

Explore Deloitte's M&A life sciences and health care leadership presence and topical discussions concurrent to the J.P. Morgan Health Care Investor Conference.

Learn about Deloitte’s presence concurrent to the conference

Download our full list of leadership sessions

Our annual Deloitte leadership sessions concurrent to J.P. Morgan Health Care Investor Conference the will be held Monday, January 7 – Thursday, January 10, 2019 at Martin Lawrence Galleries (366 Geary Street). The leadership sessions are Deloitte-hosted 1-1 meetings for topics across the life sciences & health care industry & M&A. Meeting space is located next door to the Westin St. Francis.

Download
us-three-towers-icon.jpg (200×200)  

Life sciences and health care M&A trends and investment opportunities (US leaders)

  • Susan Dettmar, US leader, M&A consultative services, Deloitte Consulting LLP
  • Simon Gisby, managing director, national practice leader life sciences and health care, Deloitte Corporate Finance LLC
  • Phil Pfrang, partner, global life sciences and health care M&A transaction services leader, Deloitte & Touche LLP
us-green-bar.jpg (694×2)
us-white-gear-icon.jpg (200×200)  

M&A trends in oncology

us-green-bar.jpg (694×2)
 

Digital therapeutics: Driving convergence between pharma and technology

  • Brett Davis, principal, Deloitte Consulting LLP
  • Susan Dettmar, US leader, M&A consultative services, Deloitte Consulting LLP
us-green-bar.jpg (694×2)
 

The future of health: Navigating the evolving ecosystem

  • Neal Batra, principal, Deloitte Consulting LLP
  • Simon Gisby, managing director, national practice leader life sciences and health care, Deloitte Corporate Finance LLC
  • Dr. Rohan Hammett, partner, Deloitte Touche Tohmatsu
  • Amry Junaideen, partner, life sciences and health care leader, Deloitte & Touche LLP
us-green-bar.jpg (694×2)
 

Investing in health tech: Health care’s new frontier

  • Simon Gisby, managing director, national practice leader life sciences and health care, Deloitte Corporate Finance LLC
  • James Gorayeb, partner, Deloitte & Touche LLP
  • Pete Micca, partner, life sciences and health care, Deloitte & Touche LLP
us-green-bar.jpg (694×2)
us-white-stethoscope-icon.jpg (200×200)  

Maximizing value in a divestiture process: How to be successful in sale processes, carveouts, spins and IPOs

  • Chris Caruso, partner, M&A transaction services, Deloitte & Touche LLP
  • Nick Cirignano, managing director, life sciences and health care, Deloitte Corporate Finance LLP
  • Jenny Gilmore, managing director, advisory, Deloitte & Touche LLP
  • Jeremy Martin, senior manager, M&A transaction services, Deloitte & Touche LLP
us-green-bar.jpg (694×2)
us-white-hospital-building-icon.jpg (200×200)  

Outsourced services to health plans

  • James Gorayeb, partner, Deloitte & Touche LLP
us-green-bar.jpg (694×2)
us-white-star-icon.jpg (200×200)  

Winning strategies for commercial success of nextgen therapies

  • Sanjay Srivastava, PhD, senior manager, Deloitte Consulting LLP
us-green-bar.jpg (694×2)
 

Behavioral health sector investing

  • Bill Siren, managing director, Deloitte Consulting LLP
us-green-bar.jpg (694×2)
 

Post-acute Care (“PAC”): Alignment dynamics and emerging trends in continuing care network development

  • Lisa Ahern, principal, Deloitte Consulting LLP
  • Todd Patnode, managing director, leader of Deloitte’s health care turnaround and restructuring practice
  • Dan Wilson, managing director, Deloitte Transactions and Business Analytics LLP
us-green-bar.jpg (694×2)
 

Alternative payment models: What’s driving the wave of change with providers and payers

  • Mark J. Bethke, managing director, Deloitte Consulting LLP
  • Kumar Kanisan, senior manager, Deloitte Consulting LLP
us-green-bar.jpg (694×2)
us-white-first-medical-kit-icon.jpg (200×200)  

Disruptive and innovation driven M&A

  • Anna Samanta, partner, EMEA life sciences M&A lead, Deloitte Switzerland
us-green-bar.jpg (694×2)
us-white-gear-icon.jpg (200×200)  

Life sciences & health care: Regulatory update

us-green-bar.jpg (694×2)
us-white-hospital-building-icon.jpg (200×200)  

Cybersecurity in the digital health age: What every investor/acquirer needs to know

  • Russell Jones, partner, and Deloitte risk and financial advisory, Deloitte & Touche LLP
us-green-bar.jpg (694×2)
 

Outsourced pharma services: Sectors and companies to watch

  • Dawn Anderson, managing director, R&D life sciences, Deloitte Consulting LLP
  • Amar Shah, director, life sciences and health care, Deloitte LLP
us-green-bar.jpg (694×2)
 

Physician practice management and specialty EMR

  • Nick Massiello, specialist leader, Deloitte Consulting LLP
us-green-bar.jpg (694×2)
us-white-pill-icon.jpg (200×200)  

Global life sciences and health care M&A trends and investment opportunities (global leaders)

  • Xander Alpherts, corporate finance partner, health care M&A leader, Deloitte Australia
  • Richard Baderman, IT M&A transaction services partner, Deloitte United Kingdom
  • Simon Brew, partner, Deloitte United Kingdom
  • Carrie Chen, China financial advisory leader, corporate finance partner, Deloitte China
  • Tal Chen, global technology alliances practice leader, partner, Deloitte Israel
  • Jason Ding, managing director, corporate finance, life sciences and health care practice, Deloitte Canada
  • Kazuhisa Go, corporate finance managing director, Deloitte Japan
  • Stav Gregoriou, M&A transaction services director, Deloitte United Kingdom
  • Rohan Hammett, consulting partner, Deloitte Australia
  • John Haughey, lead partner for life sciences and health care for North West Europe, Deloitte United Kingdom  
  • Tim Hayden, M&A transaction services senior manager, Deloitte Canada
  • Masafumi Ito, M&A transaction services partner, Deloitte Japan
  • David Jones, European financial advisory leader, UK corporate finance partner, Deloitte United Kingdom
  • Andy Khanna, corporate finance partner, financial advisory life sciences leader, Deloitte India
  • Andreas Korten, M&A transaction services partner, Deloitte Germany
  • Dr. Sebastian Krolop, Monitor Deloitte partner, Deloitte US
  • Susana Novo, Mexico life sciences and health care corporate finance lead partner, Deloitte Mexico
  • Phil Pfrang, global life sciences and health care financial advisory managing partner, Deloitte US
  • Jan Rattay, M&A transaction services partner, Deloitte United Kingdom
  • Anthony Reid, director, Deloitte United Kingdom
  • Anna Samanta, EMEA life sciences M&A lead partner, Deloitte Switzerland
  • Amar Shah, corporate finance director, Deloitte United Kingdom
  • Bill Stamatis, Canadian life sciences and health care lead partner, Deloitte Canada
  • Colin Terry, United Kingdom/Swiss life sciences partner, Deloitte United Kingdom
  • Michael van der Boom, M&A transaction services partner, Deloitte Switzerland
  • Dr. Loke Wai Chiong, Southeast Asia health care sector leader partner, Deloitte Singapore
  • Chris Woolley, United Kingdom life sciences lead partner, Deloitte United Kingdom
us-green-bar.jpg (694×2)
 

Can overseas tech acquisition cure China’s health care woes?

us-green-bar.jpg (694×2)

Disruption and investment strategies in the generics pharma industry

  • Faith Glazier, principal, life science generics segment leader, Deloitte LLP
us-green-bar.jpg (694×2)
us-three-towers-icon.jpg (200×200)

Life sciences and health care return on capital analysis

  • Teresa Leste, principal, strategy practice leader, Deloitte Consulting LLP
us-green-bar.jpg (694×2)


Maximizing value in a divestiture process: How to be successful in sale processes, carveouts, spins and IPOs

  • Chris Caruso, partner, M&A transaction services, Deloitte & Touche LLP
  • Nick Cirignano, managing director, life sciences and health care, Deloitte Corporate Finance LLP
  • Jenny Gilmore, managing director, advisory, Deloitte & Touche LLP
  • Jeremy Martin, senior manager, M&A transaction services, Deloitte & Touche LLP

Fullwidth SCC. Do not delete! This box/component contains JavaScript that is needed on this page. This message will not be visible when page is activated.

Get in touch

Susan Dettmar

Susan Dettmar

US Leader, M&A Consultative Services

Susan is a Principal with Deloitte Consulting LLP and leads the M&A Consultative Services practice. Susan has spent over 20 years focused on M&A, predominantly Post-Merger Integration and Divestiture.... More

Philip Pfrang

Philip Pfrang

Partner | Life Sciences & Health Care

Phil is the Global managing partner of Deloitte’s Health Care & Life Sciences Financial Advisory Practice. Phil has more than 27 years of M&A experience and has assisted clients with more than 1,000 c... More